Add-on omalizumab in children with severe allergic asthma: A 1-year real life survey

European Respiratory Journal

Volumn 42, Issue 5, 2013, Pages 1224-1233

  Deschildre, Antoine ^a   Marguet, Christophe ^b   Salleron, Julia ^a   Pin, Isabelle ^c   Rittié, Jean Luc ^d   Derelle, Jocelyne ^e   Taam, Rola Abou ^f   Fayon, Mickael ^g   Brouard, Jacques ^h   Dubus, Jean Christophe ⁱ   Siret, Daniel ^j   Weiss, Laurence ^k   Pouessel, Guillaume ^l   Beghin, Laurent ^a   Just, Jocelyne ^m  

^a UNIV LILLE   (France)

^b HÔPITAL CHARLES NICOLLE   (France)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

^d HÔPITAL DES ENFANTS   (France)

^e CHU NANCY BRABOIS   (France)

^f HÔPITAL NECKER ENFANTS MALADES   (France)

^g BORDEAUX UNIVERSITY HOSPITAL   (France)

^h CAEN UNIVERSITY HOSPITAL   (France)

ⁱ AIX MARSEILLE UNIVERSITY   (France)

^j Service de Pédiatrie   (France)

^k HÔPITAL DE HAUTEPIERRE   (France)

^l CH de Roubaix   (France)

^m ARMAND TROUSSEAU HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FLUTICASONE PROPIONATE; IMMUNOGLOBULIN E; OMALIZUMAB; SHORT ACTING DRUG;

ABDOMINAL PAIN; ADD ON THERAPY; ADULT; ALLERGIC ASTHMA; ALLERGIC RHINITIS; ANAPHYLAXIS; ARTICLE; ASTHENIA; ATOPIC DERMATITIS; BODY MASS; CHEMOSENSITIZATION; CHILD; COMORBIDITY; CONTROLLED STUDY; DISEASE CONTROL; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOOD ALLERGY; FORCED EXPIRATORY FLOW; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEADACHE; HEALTH CARE UTILIZATION; HUMAN; INJECTION SITE PAIN; INTENSIVE CARE UNIT; LUNG FUNCTION; LUNG FUNCTION TEST; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; MYALGIA; OBESITY; OBSERVATIONAL STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TERTIARY HEALTH CARE; URTICARIA;

ADMINISTRATION, ORAL; ADOLESCENT; ADRENAL CORTEX HORMONES; ANDROSTADIENES; ANTI-ALLERGIC AGENTS; ANTI-ASTHMATIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; CHILD; DRUG THERAPY, COMBINATION; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN E; MALE; RESPIRATORY FUNCTION TESTS; TREATMENT OUTCOME;

EID: 84880783880     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00149812     Document Type: Article

References (29)

1. Lang A, Carlsen KH, Haaland G, et al. Severe asthma in childhood: assessed in 10 year olds in a birth cohort study. Allergy 2008; 63: 1054-1060.
2. Hedlin G, Bush A, Lødrup Carlsen K, et al. Problematic severe asthma in children, not one problem but many: A GA2LEN initiative. Eur Respir J 2010; 36: 196-201.
3. Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60: 309-316.
4. Busse WW, Morgan WJ, Gergen PJ, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med 2011; 364: 1005-1015.
5. Lanier B, Bridges T, Kulus M, et al. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol 2009; 124: 1210-1216.
6. Milgrom H, Berger W, Nayak A, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 2001; 108: E36.
7. Kulus M, Hebert J, Garcia E, et al. Omalizumab in children with inadequately controlled severe allergic (IgEmediated) asthma. Curr Med Res Opin 2010; 26: 1285-1293.
8. Brodlie M, McKean MC, Moss S, et al. The oral corticosteroid-sparing effect of omalizumab in children with severe asthma. Arch Dis Child 2012; 97: 604-609.
9. Brusselle G, Michils A, Louis R, et al. "Real-life" effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study. Respir Med 2009; 103: 1633-1642.
10. Cazzola M, Camiciottoli G, Bonavia M, et al. Italian real-life experience of omalizumab. Respir Med 2010; 104: 1410-1416.
11. Rodrigo GJ, Neffen H, Castro-Rodriguez JA. Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: A systematic review. Chest 2011; 139: 28-35.
12. Berger W, Gupta N, McAlary M, et al. Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma. Ann Allergy Asthma Immunol 2003; 91: 182-188.
13. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2012. www.ginasthma.org/documents/4 Date last accessed: September 10, 2013.
14. Lødrup Carlsen KC, Hedlin G, Bush A, et al. PSACI (Problematic Severe Asthma in Childhood Initiative) group. Assessment of problematic severe asthma in children. Eur Respir J 2011; 37: 432-440.
15. Chipps BE, Szefler SJ, Simons FE, et al. Demographic and clinical characteristics of children and adolescents with severe or difficult-to-treat asthma. J Allergy Clin Immunol 2007; 119: 1156-1163.
16. Lowe PJ, Tannenbaum S, Gautier A, et al. Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma. Br J Clin Pharmacol 2009; 68: 61-76.
17. Lang A, Mowinckel P, Sachs-Olsen C, et al. Asthma severity in childhood, untangling clinical phenotypes. Pediatr Allergy Immunol 2010; 21: 945-953.
18. Illi S, von Mutius E, Lau S, et al. Perennial allergen sensitisation early in life and chronic asthma in children: A birth cohort study. Lancet 2006; 368: 763-770.
19. Borish L, Chipps B, Deniz Y, et al. Total serum IgE levels in a large cohort of patients with severe or difficult-totreat asthma. Ann Allergy Asthma Immunol 2005; 95: 247-253.
20. Sears MR, Burrows B, Flannery EM, et al. Relation between airway responsiveness and serum IgE in children with asthma and in apparently normal children. N Engl J Med 1991; 325: 1067-1071.
21. Naqvi M, Choudhry S, Tsai HJ, et al. Association between IgE levels and asthma severity among African American, Mexican, and Puerto Rican patients with asthma. J Allergy Clin Immunol 2007; 120: 137-143.
22. Fitzpatrick AM, Gaston BM, Erzurum SC, et al. Features of severe asthma in school-age children: Atopy and increased exhaled nitric oxide. J Allergy Clin Immunol 2006; 118: 1218-1225.
23. Carroll WD, Lenney W, Child F, et al. Asthma severity and atopy: how clear is the relationship?Arch Dis Child 2006; 91: 405-409.
24. de Blic J, Boucot I, Pribil C, et al. Control of asthma in children: still unacceptable? A French cross-sectional study. Respir Med 2009; 103: 1383-1391.
25. Just J, Gouvis-Echraghi R, Rouve S, et al. Two novel severe asthma phenotypes identified during childhood using a clustering approach. Eur Respir J 2012; 40: 55-60.
26. Roberts G, Patel N, Levi-Schaffer F, et al. Food allergy as a risk factor for life-threatening asthma in childhood: A case-controlled study. J Allergy Clin Immunol 2003; 112: 168-174.
27. Neukirch C, Henry C, Leynaert B, et al. Is sensitization to Alternaria alternata a risk factor for severe asthma? A population-based study. J Allergy Clin Immunol 1999; 103: 709-711.
28. Randriamanantany ZA, Annesi-Maesano I, Moreau D, et al. Alternaria sensitization and allergic rhinitis with or without asthma in the French Six Cities study. Allergy 2010; 65: 368-375.
29. Milgrom H, Fowler-Taylor A, Vidaurre CF, et al. Safety and tolerability of omalizumab in children with allergic (IgE-mediated) asthma. Curr Med Res Opin 2011; 27: 163-169.